Incube Labs, LLC

Rani Therapeutics, LLC

Cardiac Pathways Corporation

Intrapace, Inc.

Other

Spinal Modulation, Inc.

Leland Stanford Junior University

Zonare Medical Systems, Inc.

Percusurge, Inc.

Medtronic Vascular, Inc.

Tc1 LLC

Medtronic Ave, Inc.

Vidamed, Inc.

Supra Products, Inc.

Fox Hollow Technologies, Inc.

Mir A Imran

Mir Hashim

Joel M Harris

Radhika Korupolu

Deepak R Gandhi

Ted W Layman

Mark L Pomeranz

Daniel Huan Kim

Olivier K Colliou

Sharon L Lake

Mercedes Morales

Chang Jin Ong

Eyad Kishawi

Baber R Syed

Harm TenHoff

Jeffery M Kramer

Emily Arnsdorf

Dennis L Brooks

Sanjay V Patel

Brian J Mossop

Trevor J Powles

Glen W McLaughlin

Timothy J Hughes

Richard W O'Connor

Timothy H Williams

Paul Spehr

Greg Method

Talat Imran

Dignah B Quiachon

Elaine To

Peter Herrmann

Gholam-Reza Zadno-Azizi

Brian A Glynn

Christopher R Clare

Albert J Highe

Charles R Brynelsen

Sara Ansaloni

Ben Tranchina

Kyle Horlen

Ken Wong

Timothy John Williams

Rose Province

Albert G Burdulis, Jr

Raj Subramaniam

Kevin Nason

Elmar Fischer

John C Potosky

Lu Wang

Patsy A Gingell

Osamu Katoh

Roger J Guidi

Huma Arastu

Rekha Vaidyanathan

Andrew Mangogna

Celso J Bagaoisan

Hung V Ha

Henry Bourang

Brett Allen Follmer

Lynn H Elliott

Dean P Andersen

Ronald Jay Berenson

Mukund R Patel

Sivette Lam

Steve Andrew Kolenik

Kurt D Sparks

Anant V Hegde

Gholam Reza Zadno-Azizi

Darren R Sherman

Troy J Chapman

James M Brennan

Phillip G Morgan

Cecily M Hillsman

Edward M Gillis

Susan M Pietroski

William D Lipps

Matthew Harrison

Vikram Malhotra

George Andrew Mangogna

Ketan P Muni

Michael Francis Wei

Arturo S Rosqueta

Theodore C Ormsby

Alois A Langer

Donald Chin

Jeffrey S Frisbie

Stanley M Bach, Jr

Kevin H Van Bladel

Fred I Linker

Vernon L Speicher

Keith S Clark

Xufeng Xi

Umit Tarakci

Linh A Dinh

Philip C Kinney

Leon V Rudakov

Kevin T Larkin

Nicholas C DeBEER

Andrew L Lerohl

Kamran Behzadian

Jeffrey W Simpson

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Some embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. The device comprises a capsule sized to be swallowed and pass through the intestinal tract. The capsule can include at least one guide tube, one or more tissue penetrating members positioned in the guide tube, a delivery member, an actuating mechanism and a release element. The release element degrades upon exposure to various conditions in the intestine so as to release and actuate the actuating mechanism. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Swallowable drug delivery device and methods of drug delivery

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade within the wall to release the drug to produce a therapeutic effect. The preparation can be coupled to a delivery mechanism having one or more balloons or other expandable devices which are expandable responsive to a condition in the small intestine or other GI lumen to advance the preparation out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Device, system and methods for the oral delivery of therapeutic compounds

Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract.

Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins

A lead device is provided for a medical treatment apparatus, where the lead device includes protruding anchoring mechanisms for anchoring the lead device in tissue. The anchoring mechanism include permanent anchoring mechanisms, or a combination of permanent and dissolvable anchoring mechanisms, to anchor the device in tissue. The anchoring mechanism resists migration of the lead device in at least one or both axial directions.

Anchor system for retaining a device in tissue

Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and/or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and/or degraded within the GI tract.

Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device

Embodiments provide methods and apparatus for manufacturing a microtablet from a precursor material such as a pharmaceutical powder. Various embodiments provide a method which includes compressing the powder to form a compressed mass of a selected density and repeatedly compacting the compressed mass to increase the density of the compressed mass and form a microtablet. Related methods and apparatus are provided.

Method and apparatus for manufacturing microtablets

Embodiments of the invention provide apparatus, systems and methods for stimulating tissue in the urinary tract to initiate or facilitate urination. One embodiment provides an external urinary sphincter stimulation (EUSS) catheter for stimulating the external urinary sphincter (EUS), where the EUSS catheter includes nerve stimulation electrodes (NSES) for delivering current to nerves within or around the EUS in order to relax the EUS prior to urination. Other embodiments provide a system for stimulating the EUS including the EUSS catheter and a controller operatively coupled to the EUSS catheter, where the controller includes a pulse generator for delivering current to the NSES. Other embodiments provide methods for positioning the EUSS catheter in the patient's body including in the EUS using a urethral approach. Embodiments of the invention are particularly useful for initiating and/or controlling urination for patients who have lost the ability to voluntarily urinate due to neurogenic bladder dysfunction.

Device, systems and methods for treatment of neurogenic bladder

An embodiment of an ingestible device for the delivery of a therapeutic agent includes a swallowable outer shell and a delivery mechanism within the outer shell. The delivery mechanism includes an expandable enclosure. The delivery mechanism is triggerable in situ within a gastrointestinal (GI) tract of a body to expand multiple regions of the expandable enclosure to an expanded state at a delivery location within the body. The multiple regions include a head region and a tail region with a protective recess defined between the head region and the tail region, and a retention region within the protective recess. A dimension of the retention region as expanded is less than a dimension of the head region as expanded and less than a dimension of the tail region as expanded. The ingestible device includes a shaped composition disposed at the retention region.

Ingestible device with expandable enclosure

Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food.

Method for treating diabetes and other glucose regulation disorders using stem cells

Embodiments provide swallowable devices, preparations and methods for delivering therapeutic agents (TAs) within the GI tract such as antibodies (AP-antibodies) or other proteins which neutralize PCSK9 molecules. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations that are configured to be contained within the capsule, advanced from the capsule into the IW and/or peritoneum and degrade to release the TA into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW. Embodiments are particularly useful for delivery of AP-antibodies and related TA's for the treatment of cholesterol, lipid and related conditions where such TAs are poorly absorbed and/or degraded within the GI tract.

PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Embodiments of the invention provide multi-stage biodegradable drug delivery platforms and methods for the subcutaneous delivery of therapeutic agents (TA). Embodiments of the platform may be configured to subcutaneously deliver a first dose of a first TA which is absorbed into the body and/or blood stream (BBS) to produce a first therapeutic effect for a first selectable time period (STP), and subsequently after a second STP, deliver a second dose of a second TA which is absorbed into the BBS to produce a second therapeutic effect for a third STP. An embodiment of the platform may comprise a body having a tissue-penetrating end, a primary cavity having a first TA dose and a shell having a secondary cavity having a second TA dose. The first TA dose is released after the first STP and the second TA dose is released after the second STP by biodegradation of the shell.

Multi-stage biodegradable drug delivery platform

Devices, systems and methods are provided for targeted treatment of a variety of conditions, particularly conditions that are associated with or influenced by the nervous system, such as pain. Targeted treatment of such conditions is provided with minimal deleterious side effects, such as undesired motor responses or undesired stimulation of unaffected body regions. This is achieved by directly neuromodulating a target anatomy associated with the condition while minimizing or excluding undesired neuromodulation of other anatomies.

Selective stimulation systems and signal parameters for medical conditions

Embodiments of the invention provide apparatus and methods for stimulating L cells in the intestinal tract to produce incretins for the treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for the treatment of diabetes by electrically stimulating L-cells to secrete incretins to stimulate or otherwise modulate the production of insulin. Particular embodiments provide a swallowable capsule for stimulating L-cells in the intestinal tract as the capsule moves through the tract. The capsule can include two or more electrodes for providing electrical stimulation to L-cells, a power source for powering one or more components of the capsule, a sensor for sensing the location of the capsule in the intestinal tract; a controller and a waveform generator for generating the electrical signals emitted by the electrodes to stimulate the L-cells to secrete incretins such as GLP-1 to stimulate insulin production for glucose regulation of diabetic conditions.

Swallowable capsule and method for stimulating incretin production within the intestinal tract

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Method of delivering insulin into a lumen of the intestinal tract using a swallowable drug delivery device

Embodiments of the invention provide swallowable devices, preparations, and methods for delivering drugs and other therapeutic agents within the GI tract. Particular embodiments provide a swallowable device such as a capsule for delivering drugs or other therapeutic agents (TA) into a wall of the GI tract such as the stomach or small intestine. The swallowable device comprises a sensor, a combustible propellant (CP) and a therapeutic agent preparation (TAP) comprising at least one TA. The sensor triggers the CP to ignite and propel the TAP into the wall of the GI tract in response to an external condition or change in external condition. Embodiments of the invention are particularly useful for orally delivering drugs or other TAs which are degraded within the GI tract and require parenteral injection.

Propulsive drug delivery from a swallowable device into a patients intestinal tract

Growing community of inventors

Palo Alto, CA, United States of America

Mir A Imran